Table 1.
Description of baseline characteristics at cohort entry
| Any AP (n=7118) | Cefepime (n=5274) | Meropenem (n=3625) | Piperacillin-tazobactam (n=2463) | |
|---|---|---|---|---|
| Patient age (years), median (IQR) | 61 (51–71) | 62 (52–71) | 60 (50–69) | 61 (51–70) |
| Male, n (%) | 4021 (56.5) | 3037 (57.6) | 2078 (57.3) | 1380 (56.0) |
| Race, n (%) | ||||
| Caucasian | 4782 (67.2) | 3492 (66.2) | 2579 (71.1) | 1648 (66.9) |
| African American | 1860 (26.1) | 1417 (26.9) | 804 (22.2) | 661 (26.8) |
| Other | 476 (6.7) | 365 (6.9) | 242 (6.7) | 154 (6.3) |
| Charlson Comorbidity Index score, median (IQR) | 6 (4–8) | 6 (4–9) | 6 (4–8) | 6 (4–8) |
| Comorbid conditions, n (%) | ||||
| Dementia | 198 (2.8) | 159 (3.0) | 75 (2.1) | 69 (2.8) |
| Congestive heart failure | 2648 (37.2) | 2108 (40.0) | 1395 (38.5) | 835 (33.9) |
| Chronic obstructive pulmonary disease | 2849 (40.0) | 2161 (41.0) | 1485 (41.0) | 936 (38.0) |
| Liver disease | 2104 (29.6) | 1529 (29.0) | 1226 (33.8) | 742 (30.1) |
| Renal disease | 2506 (35.2) | 1968 (37.3) | 1315 (36.3) | 815 (33.1) |
| Diabetes | 2900 (40.8) | 2146 (40.7) | 1485 (41.0) | 1012 (41.1) |
| Neoplastic disease | 2413 (33.9) | 1876 (35.6) | 1316 (36.1) | 815 (33.1) |
| HIV/AIDS | 107 (1.5) | 86 (1.6) | 58 (1.6) | 31 (1.3) |
| Cohort entry date relative to admission date (days), median (IQR) | 0 (0–2) | 1 (0–4) | 4 (0–11) | 1 (0–4) |
| Admission to ICU on or prior to cohort entry | 3806 (53.5) | 2864 (54.3) | 2241 (61.8) | 1469 (59.6) |
AP: antipseudomonal beta-lactam; IQR: interquartile range; HIV/AIDS: human immunodeficiency virus/acquired immunodeficiency syndrome; ICU: intensive care unit